Serum BAFF level and its correlations with various disease parameters in patients with systemic sclerosis and systemic lupus erythematosus

Egyptian Rheumatologist

Volumn 33, Issue 1, 2011, Pages 45-51

  Fawzy, Samar M ^a   Gheita, Tamer A ^a   El Nabarawy, Eman ^a   El Demellawy, Heba H ^b   Shaker, Olfat G ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b BENI SUEF UNIVERSITY   (Egypt)

Author keywords

BAFF; MRSS; SLEDAI; SLICC; Systemic lupus erythematosus; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; CORTICOSTEROID; HYDROXYCHLOROQUINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPATHOGENESIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN TARGETING; SKIN EXAMINATION; SKINFOLD THICKNESS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

EID: 84877776277     PISSN: 11101164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejr.2010.12.001     Document Type: Article

References (36)

1. Lipsky P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001, 2:764-766.
2. Cassese G., Lindenau S., de Boer B., Arce S., Hauser A., Riemekasten G., et al. Inflamed kidneys NZB/W mice are a major site for the homeostasis of plasma cells. Eur J Immunol 2001, 31(9):2726-2732.
3. Mackay F., Browning J.L. BAFF a fundamental survival factor for B cells. Nat Rev Immunol 2002, 2:465-475.
4. Moore P.A., Belvedere O., Orr A., Pieri K., LaFleur D.W., Feng P., et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999, 285:260-263.
5. Thompson J.S., Bixler S.A., Qian F., Vora K., Scott M.L., Cachero T.G., et al. A newly identified TNF receptor that specifically interact with BAFF. Science 2001, 293:2108-2111.
6. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., et al. TACI and BCMA are receptors for TNF homologue implicated in B-cell autoimmune disease. Nature 2000, 404:995-999.
7. Yoshimoto K., Takahashi Y., Ogasawara M., Setoyama Y., Suzuki K., Tsuzaka K., et al. Aberrant expression of BAFF in T cells of systemic lupus erythematosus, which is recapitulated by a human T cell line, Loucy. Int Immunol 2006, 18(7):1189-1196.
8. Chu V.T., Enghard P., Schürer S., Steinhauser G., Rudolph B., Riemekasten G., et al. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum 2009, 60(7):2083-2093.
9. Szodoray P., Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjögren's syndrome. Scand J Immunol 2005, 62(5):421-428.
10. Von Feldt J.M. Systemic lupus erythematosus. Recognizing its various presentations. Postgrad Med 1995, 97:79-83.
11. Roschke V., Sosnovtseva S., Ward C.D., Hong J.S., Smith R., Albert V., et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002, 169(8):4314-4321.
12. Cheema G.S., Roschke V., Hilbert D.M., Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001, 44:1313-1319.
13. Zhang J., Roschke V., Baker K.P., Wang Z., Alarcón G.S., Fessler B.J., et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001, 166:6-10.
14. Stohl W., Metyas S., Tan S.M., Cheema G.S., Oamar B., Xu D., et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003, 48:3475-3486.
15. Matsushita T., Hasegawa M., Matsushita Y., Echigo T., Wayaku T., Horikawa M., et al. Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. Exp Dermatol 2007, 16(2):87-93.
16. Hasegawa M. B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis. J Dermatol 2010, 37(1):3-10.
17. van Laar J.M. B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis. Arthritis Res Ther 2010, 12(2):112.
18. Matsushita T., Hasegawa M., Yanaba K., Kodera M., Takehara K., Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006, 54(1):192-201.
19. ARA: Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
20. Le Roy E.C., Black C., Fleischmajer R., Jablonska S., Krieg T., Medsger T.A., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
21. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
22. Clements P., Lachenbruch P., Seibold J., White B., Weiner S., Martin R., et al. Inter- and intraobserver variability of total skin thickness score (modified Rodan TSS) in systemic sclerosis. J Rheumatol 1995, 22:1281-1285.
23. Liang M., Socher S., Larson M., Schur P. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989, 32:1107-1118.
24. Gladman D., Ginzler E., Goldsmith C., Fortin P., Liang M., Urowitz M., et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996, 39:363-369.
25. Bosello S., Pers J.O., Rochas C., Devauchelle V., De Santis M., Daridon C., et al. BAFF and rheumatic autoimmune disorders: implications for disease management and therapy. Int J Immunopathol Pharmacol 2007, 20(1):1-8.
26. Matsushita T., Fujimoto M., Hasegawa M., Tanaka C., Kumada S., Ogawa F., et al. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 2007, 34(10):2056-2062.
27. Saito E., Fujimoto M., Hasegawa M., Komura K., Hamaguchi Y., Kaburagi Y., et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002, 109:1453-1462.
28. Becker-Merok A., Nikolaisen C., Nossent H.C. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus 2006, 15(9):570-576.
29. Zhao L.D., Li Y., Smith M.F., Wang J.S., Zhang W., Tang F.L., et al. Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus 2010, 19(13):1534-1549.
30. Sellam J., Miceli-Richard C., Gottenberg J.E., Ittah M., Lavie F., Lacabaratz C., et al. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus. Ann Rheum Dis 2007, 66(6):790-797.
31. Ramanujam M., Davidson A. BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?. Immunol Rev 2008, 223:156-174.
32. Sanz I., Lee F.E. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010, 6(6):326-337.
33. Stohl W. A therapeutic role for BLyS antagonists. Lupus 2004, 13:317-322.
34. Kayagaki N., Yan M., Seshasayee D., Wang H., Lee W., French D.M., et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-B2. Immunity 2002, 17:515-524.
35. Baker K.P., Edwards B.M., Main S.H., Choi G.H., Wager R.E., Halpern W.G., et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003, 48:3253-3265.
36. Furie R., Stohl W., Ginzler E.M., Becker M., Mishra N., Chatham W., et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008, 10(5):R109.